Comprehensive genomic profiling identifies frequent drug-sensitive EGFR exon 19 deletions in NSCLC not identified by prior molecular testing

Clinical Cancer Research

Volumn 22, Issue 13, 2016, Pages 3281-3285

  Schrock, Alexa B ^a   Frampton, Garrett M ^a   Herndon, Dana ^b   Greenbowe, Joel R ^a   Wang, Kai ^a   Lipson, Doron ^a   Yelensky, Roman ^a   Chalmers, Zachary R ^a   Chmielecki, Juliann ^a   Elvin, Julia A ^a   Wollner, Mira ^c   Dvir, Addie ^d   Soussan Gutman, Lior ^d   Bordoni, Rodolfo ^c   Peled, Nir ^e   Braiteh, Fadi ^f   Raez, Luis ^g   Erlich, Rachel ^a   Ou, Sai Hong Ignatius ^h   Mohamed, Mohamed ^b   Ross, Jeffrey S ^a,i   Stephens, Philip J ^a   Ali, Siraj M ^a   Miller, Vincent A ^a   more..

^a FOUNDATION MEDICINE   (United States)

^b Center for Women s Healthcare and Maternal Fetal Care   (United States)

^c Rambam Health Care Campus ^*  (United States)

^d TEVA PHARMACEUTICALS   (Israel)

^e Davidoff Cancer Center   (Israel)

^f Division of Hematology and Medical Oncology   (United States)

^g Memorial Healthcare System   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; COMPREHENSIVE GENOMIC PROFILING; CONTROLLED STUDY; EGFR GENE; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENOMICS; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; NUCLEOTIDE SEQUENCE; PROCEDURES;

ADULT; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 84975256001     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1668     Document Type: Review

References (17)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
2. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95.
4. Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008;3:1439-45.
5. Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, et al. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol 2005;70:73-81.
6. Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 2007;6:661-7.
7. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013;15:415-53.
8. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-31.
9. Palmetto GBA . Analytical performance specifications for comprehensive genomic profiling (M00118, V1)[cited 2015 Jun 3]. Available from: http://www.palmettogba.com/palmetto/MolDX.nsf/ls/MolDX~9WRHPN3576?opendocument&utm-source=MDX&utm-campaign=MDXs&utm-medium=email.
10. Sequist LV, Soria J-C, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372:1700-9.
11. Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.
12. Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, et al. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer 2015;89:357-9.
13. Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in "driver-negative" lung adenocarcinomas. Clin Cancer Res 2015;21:3631-9.
14. Vignot S, Frampton GM, Soria J-C, Yelensky R, Commo F, Brambilla C, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with nonsmall-cell lung cancer. J Clin Oncol 2013;31:2167-72.
15. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 2014;13:1382-9.
16. Vignot S, Lefebvre C, Frampton GM, Meurice G, Yelensky R, Palmer G, et al. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: Evaluation of concordance between genomic and transcriptional profiles. Eur J Cancer 1990 2015;51:791-9.
17. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. J Thorac Oncol 2013;8:823-59.